[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lobular-breast-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lobular-breast-carcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,66,94,124,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639117","negativelow-hormone-receptor-and-apocrine-lobular-invasive-breast-carcinoma---a-real-world-international-cohort-study-100639117",false,"NCT07613151","Negative\u002FLow Hormone Receptor and APOcrine Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study","NAPOLI: Negative\u002FLow Hormone Receptor and APOcrine Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study","NAPOLI","Inclusion Criteria:\n\n* Female or male patients aged ≥18 years;\n* Histologically confirmed ILC, confirmed by E-cadherin loss\u002Faberrant expression and\u002For p120 cytoplasmic relocalization and\u002For CDH1 alteration;\n* HR-negative (ER \\\u003C1% and PR \\\u003C1%) or HR-low (ER and\u002For PR 1-10%) disease, as defined by ASCO\u002FCAP guidelines, is eligible regardless of HER2 status (assessed according to 2025 ASCO\u002FCAP criteria, with HER2-low and HER2-ultralow status recorded where assessable);\n* HR-positive (ER\\>10% according to the ASCO\u002FCAP guidelines) ILC is eligible only if HER2 status is positive;\n* Mixed ductal-lobular carcinomas are eligible provided that a clearly identified invasive lobular component is present and predominant (\\>50% lobular) and HR-negative\u002Flow criteria are met;\n* Stage I-III disease at diagnosis; Patients with de novo stage IV disease who underwent surgery of the primary tumor will not be included in the main study cohort but may be captured in a separate exploratory cohort for dedicated analysis;\n* Patients who underwent surgery of the primary tumor at the participating institution, either upfront or after neoadjuvant systemic treatment;\n* Diagnosis occurred between 1 January 2000 and 31 December 2025;\n* Minimum follow-up of 12 months for patients without an event, unless recurrence or death occurred earlier;\n* Local review by a dedicated breast pathologist to confirm the diagnosis and the related molecular features, with particular attention to the confirmation of apocrine morphology.\n\nExclusion Criteria:\n\n* Pure IC NST without any lobular invasive component;\n* ER or PR expression \\>10% in the invasive component, in cases with negative HER2 status;\n* In situ lobular neoplasia (lobular carcinoma in situ) without an invasive component;\n* De novo stage IV disease (such patients, if they underwent surgery of the primary tumor, will be captured in a separate exploratory cohort for a dedicated analysis)\n* Synchronous invasive BC of another dominant histology requiring systemic treatment that precludes attribution of outcomes to HR-negative\u002Flow ILC;\n* Prior invasive BC under active systemic treatment at the time of diagnosis, unless clearly documented as unrelated and not expected to confound outcomes;\n* Insufficient data or follow up","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","OBSERVATIONAL","The NAPOLI Study is a retrospective multicenter observational study designed to characterize hormone receptor-negative\u002Flow invasive lobular carcinoma of the breast. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.",[25],"Lobular Breast Carcinoma",[27,28,29],"Breast","Cancer","Lobular Neoplasia","RECRUITING","2026-08-03",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":34},"2026-05-01",{"date":38,"type":21},"2027-12-31",{"name":40,"class":41},"Istituto Oncologico Veneto IRCCS","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100513364","improving-survival-for-metastatic-lobular-breast-cancer-plumb-registry-100513364","NCT05964504","Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)","Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer","Inclusion Criteria:\n\n1. Histologically confirmed invasive lobular carcinoma. Mixed lobular\u002Fductal cancer is allowed.\n2. Age \\>=18 years\n3. Any receptor subtype.\n4. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Stage I-III breast cancer.\n2. Lack of lobular histology on tumor biopsy.\n3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).",{"count":51,"type":21},12,"10 Years","This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.",[55,25],"Metastatic Breast Cancer","2026-06-30",{"date":58,"type":34},"2026-07-02",{"date":60,"type":34},"2023-12-20",{"date":62,"type":21},"2036-02-28",{"name":64,"class":41},"University of California, San Francisco",4,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":74,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":42},"100514745","phase-2-18f-fes-petmri-for-tailoring-treatment-of-luminal-a-and-lobular-breast-cancer-100514745","NCT05982496","18F FES-PET\u002FMRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer","18F-FES PET\u002FMRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer: a Phase II Prospective Cohort Study Evaluating the Performance of FES PET\u002FMRI in Axillary Staging Compared With Axillary Surgery","FESTA","Inclusion Criteria:\n\n* Female patients, age\\>= 18 yrs, diagnosed with primary or advanced breast cancer\n* LumA or ER-positive Lobular subtypes\n\n  * candidates to surgery as first treatment regardless of cN\n  * ER-positive Her2 negative BC with ki67\\>10%\n\nExclusion Criteria:\n\n* ER-negative tumors\n* Pregnancy;\n* Contraindication to PET;\n* Contraindication to MRI;\n* Claustrophobia;\n* Allergy to the MR contrast agent;\n* Severe renal insufficiency","FEMALE",{"count":76,"type":21},119,"INTERVENTIONAL",[79],"PHASE2","Study hypothesis is that combining the advantages of hybrid PET\u002FMRI and the high sensitivity\u002Fspecificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.",[82,25,83,84,85],"Breast Cancer Female","PET\u002FMRI","Axillary Lymphadenopathy","Luminal A Breast Cancer","2026-06-09",{"date":88,"type":34},"2026-06-12",{"date":86,"type":34},{"date":91,"type":21},"2029-12-01",{"name":93,"class":41},"Università Vita-Salute San Raffaele",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":74,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":77,"phases":104,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100630102","phase-2-a-study-of-the-impact-of-endocrine-therapy-on-surgical-outcomes-in-people-with-lobular-breast-cancer-100630102","NCT07483307","A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer","Impact of Neoadjuvant Endocrine Therapy on Surgical Outcomes in Patients With Stage 2 to 3 Invasive Lobular Carcinoma: A Prospective Study","Inclusion Criteria:\n\n* Written informed consent by participant or legally authorized representative\n* Postmenopausal women aged ≥50 years with biopsy-proven cT2-T3 N0-1 ILC who opt to undergo and are medically fit to undergo BCS at enrollment.\n* Tumors of the ER+\u002FHER2- subtype, defined as:\n\n  1. ER+: Positive for ER staining as indicated by ≥10% immunoreactive tumor nuclei.\n  2. HER2-: Immunohistochemistry assay demonstrating no or faint staining in ≤10% of tumor cells (IHC 0 or 1+) or negative by dual probe in situ hybridization assay.\n\nExclusion Criteria:\n\n* Patients with prior ipsilateral breast cancer.\n* Patients with advanced regional disease (cN2\u002FcN3) or stage 4 disease.\n* Patients who would benefit from neoadjuvant chemotherapy, per the treating medical oncologist.\n* Patients who are not candidates for definitive breast surgery (inoperable or stage 4 disease).\n* Patients with gadolinium allergy, precluding the use of breast MRI.","50 Years",{"count":103,"type":21},176,[79],"The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).",[107,108,109,110,25],"Breast Cancer","HER2-negative Breast Cancer","HER2 Negative Breast Carcinoma","ER+ Breast Cancer",[107,108,109,110,112,113,114],"26-095","Memorial Sloan Kettering Cancer Center","Lobular Breast Cancer","2026-06-02",{"date":117,"type":34},"2026-06-04",{"date":119,"type":34},"2026-03-13",{"date":121,"type":21},"2030-03-13",{"name":113,"class":41},7,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":77,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":42},"100521277","phase-2-biomarkers-to-detect-endocrine-therapy-resistance-100521277","NCT06067503","Biomarkers to Detect Endocrine Therapy Resistance","Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer","Inclusion Criteria:\n\n1. Willing to provide informed consent\n2. Individuals at least 18 years of age\n3. Have biopsy-proven ER\u002FPR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC) and HER2-negative advanced or metastatic LBC starting new standard of care endocrine therapy\n4. Adequate organ function as indicated by standard laboratory tests (CBC, liver function tests or CMP) allowing for systemic breast cancer treatment per treating oncologist\n5. Patients with evaluable bone-only disease that is lytic or mixed lytic-sclerotic are eligible\n6. Willing to comply with all study procedures and be available for the duration of the study\n7. Disease may be measurable by RECIST 1.1 criteria or non-measurable. Lesion size must be at least 1cm. If only bone lesions present, they should be lytic or mixed lytic-sclerotic. If only liver lesions present, patient is not eligible.\n\nExclusion Criteria:\n\n1. Patients with active brain metastases\n2. Patients with liver-only disease are not eligible due to high background liver activity related to the radiopharmaceutical's hepatobiliary route of elimination\n3. Unable to lie flat during or tolerate PET\u002FCT\n4. Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP\n5. Presence of liver failure as judged by patient's treating physician\n6. Individuals who are pregnant, lactating, or planning on becoming pregnant during the study\n7. Not suitable for study participation due to other reasons at the discretion of the investigators\n8. Patients with progesterone-receptor negative disease defined as PR \\\u003C1 percent by IHC",{"count":132,"type":21},8,[79],"This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER\u002FPR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography\u002FComputed Tomography (FFNP-PET\u002FCT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET\u002FCT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.",[136,107,25],"Metastatic Cancer",[138,139,140],"Endocrine Therapy Resistance","circulating tumor cell","liquid biopsy","2026-04-06",{"date":143,"type":34},"2026-04-13",{"date":145,"type":34},"2024-04-30",{"date":147,"type":21},"2026-08",{"name":149,"class":41},"University of Wisconsin, Madison",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":77,"phases":159,"briefSummary":161,"conditions":162,"keywords":177,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":123},"100503631","a-study-of-radiation-therapy-to-treat-solid-tumor-cancer-that-has-spread-to-soft-tissue-100503631","NCT05837767","A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue","A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases","Inclusion Criteria:\n\n* Patients with biopsy confirmed advanced\u002Fmetastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines.\n* Age ≥ 18 years\n* ECOG Performance Status of 0 or 1.\n\nExclusion Criteria:\n\n* Patients who are pregnant or breastfeeding\n* Prior radiation therapy to the candidate metastatic sites under consideration for treatment (\"re-irradiation\" is disallowed).\n* Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.\n* Patients with a \"currently active\" metastatic second malignancy.\n* Patients on oral or parental corticosteroids. Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study.\n* Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities.\n* Unwilling or unable to participate in all required study evaluations and procedures.\n* Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).",{"count":158,"type":21},26,[160],"NA","The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).",[163,164,25,165,166,167,168,169,170,171,172,173,174,175,176],"Invasive Ductal Breast Carcinoma","Invasive Ductal Breast Carcinoma Stage IV","Lobular Breast Carcinoma Stage IV","Non Small Cell Lung Cancer","NSCLC","Gastrointestinal Cancer","Gastrointestinal Squamous Cell Cancer","Gastrointestinal Adenocarcinoma","Pancreatic Cancer","Bladder Cancer","Renal Cell Carcinoma","Melanoma","Sarcoma","Metastatic Solid Tumor",[163,25,166,167,168,169,171,172,173,174,175,176,178,179,180,181,182,183,184,185,113],"extra-cranial disease","lattice radiation therapy","LRT","spatially fractionated radiation therapy","SFRT","SBRT","stereotactic body radiation therapy","22-207","2026-03-27",{"date":188,"type":34},"2026-03-30",{"date":190,"type":34},"2023-07-24",{"date":192,"type":21},"2026-07-24",{"name":113,"class":41}]